Light Sciences Oncology Inc.
Light Sciences Oncology Inc. of Seattle has made an agreement with the FDA on a special protocol assessment for a Phase III clinical trial. This will allow the company to compare its light infusion therapy product with another treatment for metastatic colorectal cancer in the liver. The device provides photodynamic therapy, by using LEDs to activate talaporfin sodium. Through production of singlet oxygenmolecules, the light-activated drug induces apoptosis in cells within a defined zone around the LED array.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024